Group 1 - AEON Biopharma has appointed Rob Bancroft as President and CEO, and the Compensation Committee has approved inducement awards for him [1] - Mr. Bancroft will receive a non-qualified stock option to purchase 59,034 shares of AEON Class A common stock and 177,103 restricted stock units (RSUs) under the 2025 Employment Inducement Incentive Award Plan [2][3] - The stock option and RSUs will vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date [3] Group 2 - AEON Biopharma is focused on developing its proprietary botulinum toxin complex, ABP-450, for various therapeutic indications, initially targeting the neurosciences market [4] - ABP-450 is the same botulinum toxin complex marketed for cosmetic use by Evolus under the name Jeuveau and is manufactured in compliance with cGMP [4] - The company holds exclusive development and distribution rights for therapeutic indications of ABP-450 in the U.S., Canada, EU, UK, and other territories [4]

Core Points - AEON Biopharma has appointed Rob Bancroft as President and CEO, effective April 29, 2025, with Bancroft also joining the Board of Directors [1][2] - Bancroft has over 25 years of experience in the life sciences industry, including leadership roles at Revance Therapeutics and Allergan, where he was involved in the commercialization of BOTOX [2][3] - The company is focused on advancing its ABP-450 program along the 351(k) biosimilar regulatory pathway, aiming to bring ABP-450 to the U.S. market for all current and future BOTOX indications under a single FDA approval [2][3] Company Overview - AEON Biopharma is a clinical-stage biopharmaceutical company developing ABP-450 (prabotulinumtoxinA) for various therapeutic indications, initially targeting the neurosciences market [3] - ABP-450 is the same botulinum toxin complex currently marketed for cosmetic use as Jeuveau by Evolus and is manufactured in compliance with cGMP [3] - The product has been approved as a biosimilar in Mexico and India, with AEON holding exclusive rights for therapeutic indications in the U.S., Canada, EU, UK, and other territories [3]

– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents Commission File Number: 001-40021 AEON Biopharma, Inc. (Exact name of registrant as specified in its charter) Delaware 85-3940478 (I.R.S. Empl ...

Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Fourth Quarter 2024 and Full Year Financial Results and Provides Corporate Update – Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – IRV ...

– Initiated analytical studies in Q4 2024 to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX’s currently approved and future therapeutic indications – IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage bioph ...

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that Marc Forth, AEON’s President and Chief Executive Officer, will present a corporate overview at the Leerink Global Healthcare Conference being held March 10 – 12, 2025 in Miami, FL. Leerink Global Healthcare Conference Format: Corporate PresentationDate/time: Mond ...

IRVINE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that the Company’s Board of Directors approved a 1-for-72 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), to increase the selling price of the Company’s Common Stock in order to maintain compliance ...

IRVINE, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced that on February 3, 2025, AEON received a notice (the “Notice”) from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a stockholders’ equ ...

IRVINE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON) (the “Company”), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex under a 351(k) biosimilar pathway, today announced the closing of its previously announced firm commitment underwritten public offering. Gross proceeds to the Company were approximately $20.0 million, before deducting underwriting fees and other estimated offering expenses payable by the Company. The offering closed on ...